On December 14, 2020, Simcere Pharmaceutical Co., Ltd. (Simcere) and AlphaMa Biotechnology Co., Ltd. (AlphaMa) signed a strategic partnership agreement for new drug discovery. According to the agreement, AlphaMa will use artificial intelligence (AI) technologies and design, synthesis, and screen technologies of DNA Encoded Library (DEL) to screen the lead compounds of a series of specific targets in the field of the tumor, central nervous system and other diseases for Simcere in the next three years.

The principal of AlphaMa,”We are very happy to see the strategic cooperation between AlphaMa and Simcere. Simcere is a leading R&D-driven pharmaceutical company in China, with an R&D team of nearly 1,000 people and a wealth of pipeline products under development. We look forward to making complementary knowledge systems and capabilities between the AI&DEL technology platform of AlphaMa and the innovative drug development of Simcere, as well as upgrading the innovative drug research and development methods and tools, thereby providing more effective medicines to the patients as soon as possible.

Mr. Ren Jinsheng, founder and chairman of Simcere, said, “We are looking forward to collaborating with AlphaMa on innovative drug research and development. AI-enabled drug design has great potential and is an emerging disruptive technology that can provide technical support for the next generation of drug discovery with highly selective and ”undruggable” targets. In addition, the DEL platform improves the limitations of traditional drug screening methods. Combining combinatorial chemistry, affinity screening, DNA coding, and sequencing analysis, the DEL platform will accelerate the discovery of novel small molecules. We believe that AlphaMa’s forward-looking and pioneering R&D technology platform, is expected to accelerate the distribution of innovative drugs in key disease areas and provide patients with early access to more effective drugs.”

About Simcere

Simcere Pharmaceutical (2096.HK) is rapidly transitioning to an innovation and R&D-driven pharmaceutical company. It has been recognized as one of the top 100 pharmaceutical manufacturing enterprises of China. With the approval of the Ministry of Science and Technology, it has also established a national key laboratory of translational medicine and innovative pharmaceuticals. Adhering to the open and innovative R&D strategy, Simcere has become a strategic partner with several multinational companies and biotechnology enterprises to promote the translation of global life science achievements in China.

For more information, please visit: www.simcere.com

About AlphaMa

AlphaMa biotechnology Co., Ltd. uses artificial intelligence (AI) technology for drug screening and optimization to accelerate new drug development. We focus on the development of data-driven machine learning models for lead compound design and discovery, multi-target activity profiling, and ADMET profiling. AlphaMa cross-applies AI&DEL screening technology and forms a new AI-based DEL platform. Our platform is dedicated to facilitating the development of innovative small molecule drugs for tumor, nervous system, metabolism, and infectious diseases.

For more information, please visit：www.alphama.com.cn